Nanostics Revenue and Competitors

Edmonton, AB CA

Location

$17M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Nanostics's estimated annual revenue is currently $4.2M per year.(i)
  • Nanostics's estimated revenue per employee is $155,000
  • Nanostics's total funding is $17M.

Employee Data

  • Nanostics has 27 Employees.(i)
  • Nanostics grew their employee count by 35% last year.

Nanostics's People

NameTitleEmail/Phone
1
Founder, Board Chair and CEOReveal Email/Phone
2
Co-Founder & COOReveal Email/Phone
3
Chief Scientific OfficerReveal Email/Phone
4
Chief Commercialization OfficerReveal Email/Phone
5
Chief Technology OfficerReveal Email/Phone
6
VP Sales and MarketingReveal Email/Phone
7
VP Clinical EngagementReveal Email/Phone
8
Clinical Laboratory Manager and Senior ScientistReveal Email/Phone
9
Jr QA/RA ManagerReveal Email/Phone
10
Clinical ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M1110%N/AN/A
#2
$4.3M568%$1.7MN/A
#3
$3M3915%N/AN/A
#4
$4.2M54-4%N/AN/A
#5
$14.4M9341%N/AN/A
#6
$4.5M2926%N/AN/A
#7
$0.9M12-8%N/AN/A
#8
$3.7M24-17%N/AN/A
#9
$8.7M56-8%$100KN/A
#10
$3.3M2162%$13.4MN/A
Add Company

What Is Nanostics?

Nanostics Inc. is a private Canadian company that develops and commercializes novel and noninvasive diagnostic tests. Its core technology, ClarityDX®, uses advanced machine learning algorithms to create a disease risk score that predicts the presence of diseases. ClarityDX is applicable to a wide range of cancers and other diseases. Nanostics’ lead product, ClarityDX Prostate®, is a test that improves the accuracy of detecting clinically significant prostate cancer. Go to https://www.nanosticsdx.com/clarity-dx-prostate/ to order ClarityDX Prostate today.

keywords:N/A

$17M

Total Funding

27

Number of Employees

$4.2M

Revenue (est)

35%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.5M27N/AN/A
#2
$6.8M2723%N/A
#3
$2.7M27-43%N/A
#4
$1.9M27-39%N/A
#5
$3.8M2742%N/A